Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. - Wikidata - wikimedia - TriplyDB

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

http://www.wikidata.org/entity/Q33500473

about

Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis?Therapeutic neuroprotective agents for amyotrophic lateral sclerosis Mechanisms underlying inflammation in neurodegeneration Translational research involving oxidative stress and diseases of aging.Control of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disorders Brain arteriovenous malformation modeling, pathogenesis, and novel therapeutic targets.One universal common endpoint in mouse models of amyotrophic lateral sclerosis.Progress in therapy development for amyotrophic lateral sclerosis Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.Death Receptors in the Selective Degeneration of Motoneurons in Amyotrophic Lateral Sclerosis.Combination therapy with lenalidomide and nanoceria ameliorates CNS autoimmunity Characterization of the Contribution of Genetic Background and Gender to Disease Progression in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis: A Meta-Analysis.Targeting TNF-α to elucidate and ameliorate neuroinflammation in neurodegenerative diseases.Pharmacokinetics and tissue disposition of lenalidomide in mice.Type I Vs. Type II Cytokine Levels as a Function of SOD1 G93A Mouse Amyotrophic Lateral Sclerosis Disease Progression.Motor neuron-immune interactions: the vicious circle of ALS.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells Current Therapy of Drugs in Amyotrophic Lateral Sclerosis.Oxidative stress and neurodegenerative disorders Combination of alpha-synuclein immunotherapy with anti-inflammatory treatment in a transgenic mouse model of multiple system atrophy Selection and Prioritization of Candidate Drug Targets for Amyotrophic Lateral Sclerosis Through a Meta-Analysis Approach.An overview of investigational antiapoptotic drugs with potential application for the treatment of neurodegenerative disorders.Astrogliosis in amyotrophic lateral sclerosis: role and therapeutic potential of astrocytes Concomitant rheumatoid arthritis and amyotrophic lateral sclerosis: report of two new cases and review of literature.SOD1 and TDP-43 animal models of amyotrophic lateral sclerosis: recent advances in understanding disease toward the development of clinical treatments.Emerging drugs for amyotrophic lateral sclerosis.Cellular therapy to target neuroinflammation in amyotrophic lateral sclerosis.Moving forward in clinical trials for ALS: motor neurons lead the way please.Developing models for cachexia and their implications in drug discovery.Transcriptional analysis reveals distinct subtypes in amyotrophic lateral sclerosis: implications for personalized therapy.A retrospective review of the progress in amyotrophic lateral sclerosis drug discovery over the last decade and a look at the latest strategies.Role of Neuroinflammation in Amyotrophic Lateral Sclerosis: Cellular Mechanisms and Therapeutic Implications.Characterization of a commonly used mouse model of SMA reveals increased seizure susceptibility and heightened fear response in FVB/N mice.Lenalidomide regulates CNS autoimmunity by promoting M2 macrophages polarization.

P2860

Q26775096-9B5803FB-623C-4252-8EA5-6AF157528DA3 Q26799233-0409DC3C-D063-4DDC-B2D9-FBE76DBE55FB Q27015029-6C90F5F1-8898-414F-9E74-7010334B7DB7 Q29617977-EC4C040A-6E8A-49AB-B4F5-C367A2B5F3C0 Q30464085-7DB9A02E-9DFF-4111-96A5-3C4D3A1451D9 Q33670805-62E18496-CD8C-4366-AF1F-B9D6D1EB4411 Q33843008-809F7FF7-6BD7-4A16-8E8C-67024F46C6A5 Q33936763-BF1B8168-4A65-421A-8253-9D9C7F9FA42C Q34640800-AFDABF32-41D3-4CF3-B877-06143F0C989A Q35609611-2F4A491E-7CA1-4D1F-8244-BDA352E57303 Q35623419-C2F78496-94F5-4402-9DFC-D0D392A4E98F Q36278892-01C3CEE9-2C6B-482E-AF56-74312FCFF03A Q36299228-8D67B210-55BD-4CA8-B5B6-F5CC91871C1F Q36330960-501207B6-7B46-4BE5-9315-FC3816551C37 Q36331493-38C0C586-9D56-46C7-9D9A-6D473F317347 Q36332951-167D816F-7D55-42CE-8659-0E513B997CC3 Q36437332-30A8B429-4211-4228-94BD-551DB6739F69 Q36799584-88BFC47E-8460-43F8-99D3-8DF3A0D7E177 Q36861763-950B96A3-94AD-4CDE-B436-8161BA14D6A1 Q36925891-5EED7CF9-0A5A-41D2-BECA-5F27D69142CB Q37421024-C120F1D8-9713-4883-AAFD-194573F1D857 Q37565960-9609A572-0F8C-4FF3-8023-25268C0F0E01 Q37712723-007AC8F8-1CAF-44AA-AF02-6A9D065892E4 Q37733587-3316EF6B-0CB6-422D-8B7F-16915EB894C6 Q37794395-85497C98-79CB-4D7F-86EC-4F1C83943754 Q37831814-73F3D9FE-EBBC-4DA3-9315-A5E428F99D33 Q37894600-9B772CC0-4A1E-4FE2-9DF0-6B72AFB9E3ED Q37909351-6F620EA4-9857-4A1C-8C60-D1CAEB59ECB5 Q38150127-DA219AB7-FB9E-42BA-A480-32C9BF1294D3 Q38156505-FC77FD57-2D28-4124-903A-3E1EC3A3A7BD Q38451282-59313541-278C-41C9-A933-4F0CD63A9C9A Q38542939-1CB11552-1F67-4D16-BC13-159AAA031A4D Q38573829-466AABDD-FEA3-4852-80C9-658E02ABE4A4 Q41488070-C40E1918-713E-4C78-9206-9F97018AF2B6 Q41830164-BBBAD5A2-A41C-4F2F-90BC-F300052EA896 Q52694955-2CCF0746-7550-4429-970D-4825CAA09328

P2860

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

http://www.wikidata.org/entity/Q33500473

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@ast

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@en

type

label

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@ast

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@en

prefLabel

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@ast

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@en

P1433

Q33500473-51D2C1C0-C2B7-487D-8163-7AB2819089C9

P1476

Q33500473-61016C5D-2EB4-4269-84F9-FB232B4FAC05

P2093

Q33500473-161BE709-2725-441A-81F3-C381767A6173

Q33500473-1A2C48DE-D3AD-4B9E-8DB4-0EF4453CA55F

Q33500473-6521EF00-28E4-497F-9313-F4EA1EEF4869

Q33500473-9D8BADDD-EC6C-471A-B245-9603D25B42F4

Q33500473-A8C282A6-7D43-4D13-8AE3-162717F5466F

Q33500473-C7CF4E44-D1A8-42EF-9B23-DCE5CF1537AA

Q33500473-E97FB118-AEBA-4B09-B247-A1B06421674A

Q33500473-FB30BBCB-DB5B-4192-B7C2-41A72560B868

P2860

Q33500473-1C6F71B8-67E8-4066-9339-9A8A0C072519

Q33500473-1EFD0FF7-CA37-4226-89B7-C8321C764075

Q33500473-38ABB080-0586-4379-BE69-42F771F47DD8

Q33500473-482A233B-92EB-4F87-9BF8-E6E1A52624AB

Q33500473-4CCF5B3B-39A1-4D14-8A9A-AD7492E865E5

Q33500473-4F4A7680-50A6-4848-84C1-DA0781EB1AE5

Q33500473-57D71A8B-9096-4097-8EDB-B5993277F57C

Q33500473-8783EBF1-AF56-4C78-B1BF-3B6CBEA2F030

Q33500473-AA13295D-34AB-45E1-B635-05B96475E2E9

Q33500473-AB9F52B9-F8DA-4485-A978-D44155595809

P304

Q33500473-E474BB60-1FA7-400D-A8FA-91349AC95D5D

P31

Q33500473-4CB792D6-8B61-4FDC-81E8-2166F6711032

P356

Q33500473-8F2A0629-6CC3-41F2-B24E-D9BBA104941A

P407

Q33500473-B3E6650F-2C31-4F82-A2EE-374E740D73D3

P433

Q33500473-351BAEBB-2E2E-4735-B83A-95DF4DC8B089

P478

Q33500473-B52A15CF-B316-4B7F-8A81-F8B6888089D9

P50

Q33500473-C68B5D36-9DA1-4E9E-A332-DA006A5A6C32

P577

Q33500473-3AAA7793-4BA0-4ECC-8544-C647A7FA527F

P698

Q33500473-81822507-6498-4B43-B6BE-7091E5163130

P921

Q33500473-6548A81F-A447-440E-9530-3F424CCD4F7F

P932

Q33500473-1B0C1D65-F0B2-40C1-B8E8-256F7E5D0D1C

P356

J.EXPNEUROL.2009.08.028

P1433

Experimental Neurology

P1476

Lenalidomide (Revlimid) admini ...... amyotrophic lateral sclerosis.

@en

P2093

Arie Neymotin

http://www.w3.org/2001/XMLSchema#string

Charles Stewart

http://www.w3.org/2001/XMLSchema#string

Elizabeth Wille

http://www.w3.org/2001/XMLSchema#string

Kenneth Hensley

http://www.w3.org/2001/XMLSchema#string

M Flint Beal

http://www.w3.org/2001/XMLSchema#string

Mahmoud Kiaei

http://www.w3.org/2001/XMLSchema#string

Noel Y Calingasan

http://www.w3.org/2001/XMLSchema#string

Peter Schafer

http://www.w3.org/2001/XMLSchema#string

P2860

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

Unraveling the mechanisms involved in motor neuron degeneration in ALS

Onset and progression in inherited ALS determined by motor neurons and microglia

The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice.

The role of microglial cells in amyotrophic lateral sclerosis.

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.

Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93A-SOD1 mouse model of amyotrophic lateral sclerosis.

The evolution of thalidomide and its IMiD derivatives as anticancer agents.

P304

191-197

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EXPNEUROL.2009.08.028

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

220

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19733563

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

3979314

http://www.w3.org/2001/XMLSchema#string